tiprankstipranks
Trending News
More News >
Ypsomed Holding AG (CH:YPSN)
:YPSN
Advertisement

Ypsomed Holding AG (YPSN) AI Stock Analysis

Compare
1 Followers

Top Page

CH:YPSN

Ypsomed Holding AG

(LSE:YPSN)

Rating:61Neutral
Price Target:
CHF414.00
▲(5.61% Upside)
Ypsomed Holding AG's overall score is driven by strong financial performance, particularly in revenue growth and profitability. However, the high valuation and weak technical indicators suggest caution. The negative Free Cash Flow highlights potential risks, and the lack of earnings call data limits insight into future guidance.

Ypsomed Holding AG (YPSN) vs. iShares MSCI Switzerland ETF (EWL)

Ypsomed Holding AG Business Overview & Revenue Model

Company DescriptionYpsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
How the Company Makes MoneyYpsomed generates revenue through multiple key streams, primarily from the sale of its medical devices and systems for self-medication. This includes direct sales of insulin delivery devices to healthcare providers and pharmaceutical companies. Additionally, the company earns revenue from development partnerships with pharmaceutical firms, where it collaborates on the design and production of customized drug delivery systems. Ypsomed also benefits from recurring revenue through the sale of disposable components related to its delivery systems. Significant partnerships with major pharmaceutical companies further bolster its revenue by enabling co-development projects and expanding the market reach of its products.

Ypsomed Holding AG Financial Statement Overview

Summary
Ypsomed Holding AG shows strong revenue growth and profitability with effective cost management and operational efficiency. The balance sheet is healthy with a solid ROE and reasonable leverage. However, negative Free Cash Flow due to high capital expenditures poses a potential risk.
Income Statement
82
Very Positive
Ypsomed Holding AG has demonstrated notable revenue growth, with Total Revenue increasing from CHF 548.5 million in 2024 to CHF 748.9 million in 2025, representing a growth rate of 36.54%. The company's Gross Profit Margin is robust at 39.00%, and the Net Profit Margin is healthy at 11.69%, reflecting strong profitability. EBIT and EBITDA Margins are also solid at 15.08% and 25.49%, respectively, indicating effective cost management and operational efficiency.
Balance Sheet
75
Positive
The company's Debt-to-Equity Ratio is 0.39, which indicates a reasonable level of leverage. The Return on Equity (ROE) is strong at 12.88%, showcasing effective utilization of shareholder funds. The Equity Ratio stands at 51.08%, highlighting a balanced capital structure with a significant portion funded by equity, contributing to financial stability.
Cash Flow
68
Positive
Ypsomed Holding AG's Free Cash Flow is negative at CHF -128.9 million, primarily due to high capital expenditures. However, the Operating Cash Flow to Net Income Ratio is favorable at 1.69, suggesting that the company's operations are generating sufficient cash relative to its net income. The Free Cash Flow to Net Income Ratio is negative, indicating challenges in converting net income into free cash flow, which might be a concern if sustained.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue748.87M748.87M548.46M497.46M464.84M403.66M
Gross Profit292.06M292.07M189.05M140.59M113.82M94.83M
EBITDA176.44M190.90M161.78M137.51M92.48M63.86M
Net Income87.50M87.50M78.37M51.27M23.11M5.81M
Balance Sheet
Total Assets1.33B1.33B1.10B861.88M756.91M717.68M
Cash, Cash Equivalents and Short-Term Investments36.49M36.49M74.02M25.22M17.04M22.41M
Total Debt267.00M267.00M256.00M157.00M267.00M215.00M
Total Liabilities650.66M650.66M483.66M291.57M356.63M313.54M
Stockholders Equity679.68M679.68M617.74M562.33M392.54M395.38M
Cash Flow
Free Cash Flow-57.40M-128.95M-32.09M-39.64M-41.72M-40.75M
Operating Cash Flow148.20M148.20M163.22M129.53M85.71M85.83M
Investing Cash Flow-267.27M-267.27M-195.07M-122.02M-125.70M-106.91M
Financing Cash Flow82.25M82.25M81.07M1.26M38.12M26.67M

Ypsomed Holding AG Technical Analysis

Technical Analysis Sentiment
Negative
Last Price392.00
Price Trends
50DMA
408.64
Negative
100DMA
384.04
Positive
200DMA
368.07
Positive
Market Momentum
MACD
-2.00
Negative
RSI
42.33
Neutral
STOCH
54.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:YPSN, the sentiment is Negative. The current price of 392 is below the 20-day moving average (MA) of 395.03, below the 50-day MA of 408.64, and above the 200-day MA of 368.07, indicating a neutral trend. The MACD of -2.00 indicates Negative momentum. The RSI at 42.33 is Neutral, neither overbought nor oversold. The STOCH value of 54.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:YPSN.

Ypsomed Holding AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
CHF5.48B63.7913.49%0.55%36.54%11.60%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
$40.54B37.254.98%0.41%
$3.68B46.4020.81%0.44%
$4.83B28.1515.79%0.43%
$2.75B37.924.57%1.79%
63
Neutral
CHF4.22B21.93
2.72%5.84%8.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:YPSN
Ypsomed Holding AG
392.00
-20.81
-5.04%
ALC
Alcon
81.36
-15.52
-16.02%
MEDGF
Medacta Group SA
181.38
29.21
19.20%
SGFEF
Siegfried Holding AG
114.35
11.58
11.27%
TCHBF
Tecan Group AG
209.82
-121.42
-36.66%
CH:GALE
Galenica AG
84.95
13.47
18.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 28, 2025